Top Story

Current smoking linked to invasive fusariosis in patients with acute myeloid leukemia

December 10, 2014

Researchers at the Universidade Federal do Rio de Janeiro in Brazil determined that active smoking was associated with invasive fusariosis among patients undergoing induction remission for acute myeloid leukemia or myelodysplasia.

“Invasive fungal disease represents a major complication in patients with acute myeloid leukemia (AML) and in hematopoietic cell transplant (HCT) recipients,” the researchers wrote in Clinical Infectious Diseases. “While invasive aspergillosis is the most frequent invasive fungal disease in such patients, infections caused by other molds have been increasingly reported. Clinical features and prognostic factors of invasive fusariosis have been well characterized, but very little is known about risk factors.”

Meeting News CoveragePerspective

CD146 may serve as novel target to treat gastrointestinal GVHD

December 8, 2014
SAN FRANCISCO — A population of CD146+ and chemokine receptor 5-positive, Th17-prone T cells may serve as an early marker for patients who are at risk for…
Meeting News CoveragePerspective

Autologous HSCT evolves as standard of care for HIV-associated lymphoma

December 6, 2014
SAN FRANCISCO — Autologous hematopoietic stem cell transplantation conferred favorable outcomes in patients with HIV-associated non-Hodgkin’s or…
Brentuximab vedotin stalled Hodgkin’s lymphoma progression after autologous HSCT Meeting News Coverage

Brentuximab vedotin stalled Hodgkin’s lymphoma progression after autologous HSCT

December 6, 2014
SAN FRANCISCO — Brentuximab vedotin safely and effectively stalled disease progression in patients with Hodgkin’s lymphoma when administered early after…
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
In the Journals

Current smoking linked to invasive fusariosis in patients with acute myeloid leukemia

December 10, 2014
Researchers at the Universidade Federal do Rio de Janeiro in Brazil determined that active smoking was associated with invasive fusariosis among…
Meeting News CoveragePerspective

CD146 may serve as novel target to treat gastrointestinal GVHD

December 8, 2014
SAN FRANCISCO — A population of CD146+ and chemokine receptor 5-positive, Th17-prone T cells may serve as an early marker for patients who are…
Meeting News CoveragePerspective

Autologous HSCT evolves as standard of care for HIV-associated lymphoma

December 6, 2014
SAN FRANCISCO — Autologous hematopoietic stem cell transplantation conferred favorable outcomes in patients with HIV-associated…
Brentuximab vedotin stalled Hodgkin’s lymphoma progression after autologous HSCT Meeting News Coverage

Brentuximab vedotin stalled Hodgkin’s lymphoma progression after autologous HSCT

December 6, 2014
SAN FRANCISCO — Brentuximab vedotin safely and effectively stalled disease progression in patients with Hodgkin’s lymphoma when…
Paul Richardson In the Journals

Allogeneic transplantation achieved graft-versus-myeloma effect

November 18, 2014
Allogeneic transplantation induced sustained remissions in patients with multiple myeloma, with the greatest survival benefit observed among those…
In the Journals

Maintenance lenalidomide after allogeneic HSCT improved response in high-risk multiple myeloma

November 3, 2014
Maintenance lenalidomide after allogeneic hematopoietic stem cell transplantation was associated with greater overall response but increased acute…
Beth Trehu, MD FDA News

FDA grants fast track designation to PRM-151 for myelofibrosis

November 3, 2014
The FDA granted fast track designation to PRM-151 as a potential treatment for patients with myelofibrosis, the drug’s manufacturer…
The lack of a perfect donor shouldn’t deter clinicians or patients from considering transplant in situations where non-transplant therapy is not very effective, said Mary Horowitz, MD, chief of the division of hematology and oncology at the Medical College of Wisconsin and chief scientific director of the Center for International Blood and Marrow Transplant Research. Cover StoryPublication Exclusive

Efforts intensify to ensure accessibility, sustainability of HSCT

HemOnc Today, November 25, 2014
Hematopoietic stem-cell transplant, initially developed as a rescue therapy for patients with cancer, has evolved over the past few decades into a…
John Wagner In the Journals

Double-unit cord-blood transplant failed to extend survival in blood cancers

October 29, 2014
Children and adolescents with hematologic malignancies who underwent double-unit cord-blood transplantation experienced similar survival rates as…
FDA News

FDA grants orphan drug status to Glassia for GVHD

October 29, 2014
The FDA granted orphan drug designation to a liquid alpha-1 proteinase inhibitor for the treatment of patients with graft-versus-host disease…
More Headlines »
morganatic-roan